Form 4: Third Harmonic Bio Director Reports Option Cancellation Amidst Dissolution

A director at Third Harmonic Bio, Inc. reported the cancellation of 120,166 stock options in connection with the company's dissolution, with a liquidation distribution of $5.35 per share.

Summary

• Director Thomas P. Soloway reported a transaction involving 120,166 stock options.
• The transaction, dated August 11, 2025, is a cancellation of common stock shares.
• This cancellation is directly related to the dissolution of Third Harmonic Bio, Inc.
• The transaction involves a liquidation distribution of $5.35 per share, less the exercise price of the options.

Sentiment

Score: 1

Explanation: The company is dissolving, which is the most negative outcome for a publicly traded entity, indicating a complete cessation of operations and return of capital.

Negatives

• Third Harmonic Bio, Inc. is undergoing dissolution.
• Stock options held by a director are being cancelled as part of the dissolution.
• The company will cease to exist as an operating entity.

Risks

• The primary risk for shareholders is the complete loss of investment beyond the liquidation distribution, as the company is dissolving.
• Uncertainty regarding the final value of the liquidation distribution for all shareholders, as the filing only details the option holder's specific transaction.

Future Outlook

The company is dissolving, indicating no future operations or strategic outlook beyond the winding down process and final liquidation distributions.

Management Comments

• Represents payment of the liquidation distribution of $5.35 per share less the exercise price of such options.
• Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer.

Industry Context

The dissolution of a biotechnology company like Third Harmonic Bio, Inc. often reflects significant challenges such as clinical trial failures, inability to secure further funding, or a strategic decision to cease operations. This is a common, albeit unfortunate, outcome in the high-risk, capital-intensive biotech sector where many companies do not bring products to market.

Stakeholder Impact

• Shareholders will receive a liquidation distribution of $5.35 per share (less exercise price for options), but will lose their equity in the company as it dissolves.
• Employees are likely to be laid off as the company ceases operations.
• Customers and suppliers will be impacted as the company's operations cease.

Next Steps

• Completion of the dissolution process for Third Harmonic Bio, Inc.
• Finalization of liquidation distributions to all shareholders.

Key Dates

Recommendation

The company is dissolving, meaning its shares will cease to trade and shareholders will only receive a final liquidation distribution. Holding shares beyond this point offers no upside and only risk of further value erosion if the liquidation value is less than expected, or if there are delays. Investors should sell to realize the liquidation value or avoid further losses.

Keywords

Third Harmonic Bio, THRD, Dissolution, Liquidation, Stock Option Cancellation, SEC Form 4, Corporate Action, Shareholder Distribution